Literature DB >> 10704151

Cell cycle regulation and RNA polymerase II.

D B Bregman1, R G Pestell, V J Kidd.   

Abstract

The cell cycle and transcription by RNA polymerase II (RNAP II) are closely related. They utilize shared components. RNAP II transcriptional activity is modulated during the cell cycle. Cell cycle dependent changes in the phosphorylation status of the carboxyl-terminal domain (CTD) of the largest subunit of RNAP II (RNAP II-LS) alter transcription. Several CTD kinases are members of the cyclin-dependent kinase (cdk) superfamily, including p34cdc2 (cdk1), cdk7, cdk8, and cdk9. Each of these cdks, with their respective cyclin partners, have been linked to cell cycle regulatory events. Other CTD kinases such as casein kinase II (CKII) and c-abl have also been implicated in cell cycle dependent modifications of the CTD. In addition, the stalling of RNAP II complexes at DNA lesions helps stimulate p53 accumulation which largely determines the cell's DNA damage response, including cell cycle arrest. Alzheimer's disease pathology results partially from activation of mitotic cdks in postmitotic neurons which can phosphorylate RNAP II-LS and other targets.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10704151     DOI: 10.2741/bregman

Source DB:  PubMed          Journal:  Front Biosci        ISSN: 1093-4715


  39 in total

1.  The carboxyl-terminal domain of RNA polymerase II is phosphorylated by a complex containing cdk9 and infected-cell protein 22 of herpes simplex virus 1.

Authors:  Lizette O Durand; Sunil J Advani; Alice P W Poon; Bernard Roizman
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

2.  Covalent capture of kinase-specific phosphopeptides reveals Cdk1-cyclin B substrates.

Authors:  Justin D Blethrow; Joseph S Glavy; David O Morgan; Kevan M Shokat
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-30       Impact factor: 11.205

Review 3.  Functional evolution of cyclin-dependent kinases.

Authors:  John H Doonan; Georgios Kitsios
Journal:  Mol Biotechnol       Date:  2009-01-15       Impact factor: 2.695

Review 4.  RNA polymerase II C-terminal domain: Tethering transcription to transcript and template.

Authors:  Jeffry L Corden
Journal:  Chem Rev       Date:  2013-09-16       Impact factor: 60.622

5.  Autophosphorylation-induced degradation of the Pho85 cyclin Pcl5 is essential for response to amino acid limitation.

Authors:  Sharon Aviram; Einav Simon; Tsvia Gildor; Fabian Glaser; Daniel Kornitzer
Journal:  Mol Cell Biol       Date:  2008-09-15       Impact factor: 4.272

Review 6.  The history and future of targeting cyclin-dependent kinases in cancer therapy.

Authors:  Uzma Asghar; Agnieszka K Witkiewicz; Nicholas C Turner; Erik S Knudsen
Journal:  Nat Rev Drug Discov       Date:  2015-02       Impact factor: 84.694

7.  Disruption of the Cockayne syndrome B gene impairs spontaneous tumorigenesis in cancer-predisposed Ink4a/ARF knockout mice.

Authors:  Y Lu; H Lian; P Sharma; N Schreiber-Agus; R G Russell; L Chin; G T van der Horst; D B Bregman
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

8.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases.

Authors:  Kamil Paruch; Michael P Dwyer; Carmen Alvarez; Courtney Brown; Tin-Yau Chan; Ronald J Doll; Kerry Keertikar; Chad Knutson; Brian McKittrick; Jocelyn Rivera; Randall Rossman; Greg Tucker; Thierry Fischmann; Alan Hruza; Vincent Madison; Amin A Nomeir; Yaolin Wang; Paul Kirschmeier; Emma Lees; David Parry; Nicole Sgambellone; Wolfgang Seghezzi; Lesley Schultz; Frances Shanahan; Derek Wiswell; Xiaoying Xu; Quiao Zhou; Ray A James; Vidyadhar M Paradkar; Haengsoon Park; Laura R Rokosz; Tara M Stauffer; Timothy J Guzi
Journal:  ACS Med Chem Lett       Date:  2010-05-17       Impact factor: 4.345

Review 9.  Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents.

Authors:  A E Leitch; C Haslett; A G Rossi
Journal:  Br J Pharmacol       Date:  2009-09-23       Impact factor: 8.739

Review 10.  Emerging drug profile: cyclin-dependent kinase inhibitors.

Authors:  James S Blachly; John C Byrd
Journal:  Leuk Lymphoma       Date:  2013-07-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.